Open Access. Powered by Scholars. Published by Universities.®

Laboratory and Basic Science Research Commons

Open Access. Powered by Scholars. Published by Universities.®

The Texas Medical Center Library

2010

Lapatinib

Articles 1 - 1 of 1

Full-Text Articles in Laboratory and Basic Science Research

Understanding Acquired Resistance To Lapatinib In Breast Cancer Cells, Jen-Te Tseng Aug 2010

Understanding Acquired Resistance To Lapatinib In Breast Cancer Cells, Jen-Te Tseng

Dissertations & Theses (Open Access)

Signaling through epidermal growth factor receptor (EGFR/ErbB) family members plays a very important role in regulating proliferation, development, and malignant transformation of mammary epithelial cells. ErbB family members are often over-expressed in human breast carcinomas. Lapatinib is an ErbB1 and ErbB2 tyrosine kinase inhibitor that has been shown to have anti-proliferative effects in breast and lung cancer cells. Cells treated with Lapatinib undergo G1 phase arrest, followed by apoptosis. Lapatinib has been approved for clinical use, though patients have developed resistance to the drug, as seen previously with other EGFR inhibitors. Moreover, the therapeutic efficacy varies significantly within the patient …